Back to top
more

Recursion Pharmaceuticals (RXRX)

(Delayed Data from NSDQ)

$7.02 USD

7.02
5,503,023

-0.32 (-4.36%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $7.01 -0.01 (-0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (154 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Recursion (RXRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its second-quarter earnings release, given the absence of a marketed product.

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) closed at $8.19 in the latest trading session, marking a -1.92% move from the prior day.

Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 43.7% upside potential for Recursion Pharmaceuticals (RXRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) reachead $9.38 at the closing of the latest trading day, reflecting a +0.43% change compared to its last close.

Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 9.30% and 3.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.

Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $8.84, denoting a +0.57% change from the preceding trading day.

Recursion Pharmaceuticals, Inc. (RXRX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Recursion Pharmaceuticals (RXRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) closed at $7.84 in the latest trading session, marking a -1.26% move from the prior day.

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) closed at $7.47 in the latest trading session, marking a -1.32% move from the prior day.

Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 13.04% and 11.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Recursion Pharmaceuticals (RXRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Andrew Rocco headshot

13F Season: 3 Whales to Follow

by Andrew Rocco

Tracking 13F filings is crucial for market participants seeking to understand trends, identify potential investment opportunities, and monitor the transactions of Wall Street's most influential investors. Stock Strategist Andrew Rocco breaks down the 3 most important filings this 13F season.

Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of -5.56% and 3.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Soars 7.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 0% and 5.66%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why

by Zacks Equity Research

Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.

Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery

by Zacks Equity Research

Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.